PaySign (PAYS) AI Stock Analysis

• Market Cap: $287.87M
• Dividend Yield: N/A
• Average Volume (3M): 439.63K
• Price to Earnings (P/E): 39.8
• Beta (1Y): 1.86
• Revenue Growth: 32.61%
• EPS Growth: -8.26%
• Country: US
• Employees: 173
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Infrastructure
• EPS (TTM): 0.04
• Shares Outstanding: 55,042,890
• 10 Day Avg. Volume: 644,196
• 30 Day Avg. Volume: 439,627
• PEG Ratio: -1.05
• Price to Book (P/B): 5.28
• Price to Sales (P/S): 2.75
• P/FCF Ratio: 11.94
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 3.69
• Enterprise Value/Gross Profit: 6.16
• Enterprise Value/Ebitda: 19.20
• 1Y Price Target: $9.00
• Price Target Upside: 72.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): $80.00M

• Rating: 69 Neutral
• Price Target: $6.00 ▲(14.72% Upside)

PaySign's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company shows robust revenue growth and operational improvements, which are offset by valuation concerns and technical indicators suggesting limited short-term momentum. The absence of a dividend yield and high P/E ratio further temper the overall score.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market presence and successful product adoption, supporting long-term business sustainability.

Operational Efficiency

Improved operational efficiency enhances profitability and competitiveness, contributing to sustainable growth and cost management.

Cash Generation

Strong cash generation supports future investments and debt servicing, ensuring financial stability and growth potential.

Negative Factors

Plasma Industry Challenges

Oversupply in the plasma industry may pressure revenue and margins in the short to medium term, affecting profitability.

Regulatory Delays

Regulatory delays can hinder new product launches, impacting growth and diversification efforts in the near future.

Increased Operating Expenses

Rising operating expenses can erode profit margins, limiting the company's ability to invest in growth and innovation.

PaySign Business Overview & Revenue Model

Company Description

PaySign, Inc. is a financial technology company that specializes in providing prepaid card solutions and payment processing services. The company primarily operates in the healthcare, corporate, and consumer sectors, offering a range of products including prepaid debit cards, digital payment solutions, and card program management. PaySign's services are designed to improve cash flow and enhance payment experiences for its clients, which include businesses, government agencies, and healthcare organizations.

How the Company Makes Money

PaySign generates revenue through multiple streams, primarily by charging fees for its prepaid card programs and transaction processing services. The company's revenue model includes card issuance fees, transaction fees for point-of-sale purchases, and monthly service fees for ongoing account management. Additionally, PaySign benefits from interchange fees received from card transactions. The company has established strategic partnerships with various organizations, including healthcare providers and payment processors, which contribute to its earnings by expanding its customer base and enhancing its service offerings. These partnerships enable PaySign to deliver tailored solutions that meet the specific needs of its clients, thereby driving additional revenue growth.

PaySign Financial Statement Overview

Summary

PaySign demonstrates strong revenue growth and improving operational efficiency. Despite some pressure on net profitability, the company maintains a healthy balance sheet with low leverage and strong cash flows, positioning it well for future growth and stability. However, the relatively low net profit margin and stockholders' equity warrant careful monitoring to ensure long-term financial health.

Income Statement

PaySign showed a strong revenue growth of 23.5% over the past year, indicating a positive trajectory. The gross profit margin stands at 55.1%, which is solid for the industry. However, the net profit margin has decreased to 6.5% from 13.7% last year, indicating some profitability pressure. The EBIT margin has improved to 1.7%, recovering from negative figures in prior years, showing signs of operational improvement.

Balance Sheet

The debt-to-equity ratio is low at 0.1, indicating minimal leverage, which is beneficial for financial stability. Return on equity is 12.5%, showing reasonable profitability relative to shareholder equity. The equity ratio is 17%, which is moderate and suggests a balanced capital structure. However, the stockholders' equity is relatively low compared to total liabilities, indicating potential risk if liabilities increase.

Cash Flow

Operating cash flow increased to $22.9 million, showcasing robust cash generation capabilities. Free cash flow also showed growth, which is a positive sign for future investments and debt servicing. The operating cash flow to net income ratio is high at 6.0, indicating strong cash conversion efficiency. The free cash flow to net income ratio is 5.9, reinforcing the company's strong cash position relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	74.88M	58.38M	47.27M	38.03M	29.46M	24.12M
Gross Profit	44.80M	32.20M	24.14M	20.95M	14.71M	9.30M
EBITDA	14.38M	7.02M	3.86M	2.79M	-1.12M	-5.79M
Net Income	7.56M	3.82M	6.46M	1.03M	-2.72M	-9.14M
Balance Sheet
Total Assets	209.51M	179.03M	146.60M	108.24M	84.05M	67.83M
Cash, Cash Equivalents and Short-Term Investments	7.53M	10.77M	16.99M	9.71M	7.39M	7.83M
Total Debt	6.08M	2.93M	3.31M	3.67M	4.01M	4.33M
Total Liabilities	163.75M	148.59M	122.11M	91.95M	71.06M	54.60M
Stockholders Equity	45.76M	30.44M	24.49M	16.29M	12.99M	13.24M
Cash Flow
Free Cash Flow	9.84M	13.46M	20.57M	21.23M	12.55M	10.43M
Operating Cash Flow	18.67M	22.95M	27.62M	25.32M	15.23M	13.78M
Investing Cash Flow	-10.84M	-9.49M	-7.05M	-4.09M	-2.68M	-3.34M
Financing Cash Flow	150.32K	-466.25K	-1.12M	0.00	192.14K	-72.86K

PaySign Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAYS, the sentiment is Neutral. The current price of 5.23 is above the 20-day moving average (MA) of 5.17, below the 50-day MA of 5.52, and above the 200-day MA of 4.68, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 18.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PAYS.

PaySign Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAYS	69 Neutral	$287.87M	39.77	20.36%	―	32.61%	-8.26%
PAYO	69 Neutral	$2.05B	30.26	9.79%	―	10.58%	-45.52%
IMXI	68 Neutral	$450.54M	11.88	26.84%	―	-6.57%	-29.62%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
AVPT	61 Neutral	$2.78B	―	0.58%	―	24.71%	99.52%
RPAY	49 Neutral	$540.04M	―	-17.60%	―	-0.58%	-57.43%
BKKT	47 Neutral	$464.76M	―	-48.63%	―	101.97%	58.61%

PaySign Corporate Events

Paysign, Inc. Reports Strong Q3 2025 Financial Results

Paysign, Inc. is a financial services company specializing in prepaid card programs, pharma patient affordability, digital banking services, and integrated payment processing, primarily serving the healthcare industry. In its third quarter of 2025, Paysign reported record revenue of $21.6 million, marking a 41.6% increase from the previous year, alongside a net income rise of 54.2% to $2.22 million. The company’s Adjusted EBITDA also saw a substantial increase of 78.1% to $5.04 million, driven by significant growth in its pharma patient affordability and plasma revenue streams. Key highlights include a 141.9% increase in pharma patient affordability revenue and a 12.4% rise in plasma revenue, with the company expanding its active programs and plasma centers significantly over the past year. Paysign’s strategic expansion, including a new customer service contact center, positions it to meet growing demand and enhance service delivery. Looking forward, Paysign’s management remains optimistic about continued growth, particularly in the pharma patient affordability sector, as they anticipate further program additions and infrastructure enhancements to capitalize on emerging opportunities.

PaySign Settles Stockholder Derivative Actions

On November 25, 2024, Paysign, a company involved in financial services, entered into a Stipulation and Agreement of Settlement to resolve stockholder derivative actions pending in the United States District Court for the District of Nevada. These actions alleged violations of the Exchange Act, breaches of fiduciary duty, unjust enrichment, and waste. The settlement, which is not an admission of fault, requires Paysign to adopt corporate governance reforms and will result in the dismissal of the actions with prejudice, pending court approval. The settlement is seen as beneficial for the company and its shareholders, avoiding the costs and risks of litigation.

The most recent analyst rating on (PAYS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on PaySign stock, see the PAYS Stock Forecast page.